Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax

9 Mar 2023

Abstract excerpt

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically relevant biomarkers that predict response to 5-AZA/VEN. Here, we integrated transcriptomic, proteomic, functional, and clinical data to identify predictors of 5-AZA/VEN response. Although cultured monocytic AML cells displayed upfront...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cell death mechanisms and regulation
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36892565
DOI: 10.1158/2159-8290.cd-22-0939

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/VenetoclaxPMID 36892565Read ↗

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity Read ↗

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read ↗

A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based TherapySemantic proximity Read ↗

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapySemantic proximity Read ↗

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemiaSemantic proximity Read ↗

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signalingSemantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy BiomarkerSemantic proximity Read ↗

The rise of apoptosis: targeting apoptosis in hematologic malignanciesSemantic proximity Read ↗

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity Read ↗

Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.